GoAI
Get started
BrightPath Biotherapeutics Co., Ltd. logo

BrightPath Biotherapeutics Co., Ltd.

4594.T

JPXHealthcareBiotechnology

Open in GoAI

Latest quote

¥53.00

¥0.00 · 0.00%

Aug 24, 2:36 PM JST

4594.T company overview

Regular session · JST · Market data may be delayed.

Company profile

Company website

BrightPath Biotherapeutics Co., Ltd. specializes in the development of innovative cancer immunotherapies. Among its leading candidates is GRN-1201, currently undergoing Phase II clinical studies for non-small cell lung cancer and Phase I studies for melanoma. The company's diverse development portfolio further encompasses BP1101, a neoantigen vaccine; BP1209, a platform for personalized neoantigen cancer vaccines; and BP1401, an agonist for toll-like receptor 9. Other therapeutic avenues include an induced pluripotent stem cell (iPSC)-derived regenerated NKT cell therapy aimed at head and neck cancer, and BP2301, an autologous HER2 chimeric antigen receptor-T (CAR-T) cell therapy targeting solid tumor sarcomas. Beyond its clinical-stage assets, BrightPath Biotherapeutics is also engaged in early-stage discovery efforts for new antibodies, including BP1200, which targets CD73; BP1210, an immune checkpoint inhibitor; and additional antibody candidates such as BP1202, BP1206, and BP1211. Established in Tokyo, Japan, in 2003, the company operated as GreenPeptide Co., Ltd. until its rebranding to BrightPath Biotherapeutics Co., Ltd. in July 2017.

Industry
Biotechnology
Sector
Healthcare
Headquarters
JP
CEO
Kenichi Nagai
Listed since
Oct 22, 2015
Employees
42

Market position

Day range

Current ¥53.00

52-week range

Current ¥53.00

Open
¥53.00
Previous close
¥53.00
Volume
359.6K
0.22× average
Average volume
1.62M
Average daily volume
Market cap
4.45B JPY
Beta
1.3
Market reference 1
50-day average
¥48.24
+9.87% above average
200-day average
¥56.835
-6.75% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
5.54B JPY
P/E (TTM)
-4.14×
P/B (TTM)
4.04×
P/S (TTM)
71,806.45×
EV / EBITDA
-4.25×
Earnings yield
-16.95%
Free cash flow yield
-17.75%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
62.90%
Operating margin
-2575346.77%
Net margin
-2570440.32%
Return on equity
-55.10%
Return on assets
-50.10%
Return on invested capital
-53.00%

Financial health

Debt / equity
0×
Current ratio
15.83×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends162341%-486633%-1135606%-1784579%Gross margin, FY2021: -149.48%Gross margin, FY2022: -252.54%Gross margin, FY2023: -473.61%Gross margin, FY2024: 97.18%Gross margin, FY2025: 65.48%Operating margin, FY2021: -9579.65%Operating margin, FY2022: -27785.19%Operating margin, FY2023: -1604276.39%Operating margin, FY2024: -102464.08%Operating margin, FY2025: -1541666.67%Net margin, FY2021: -9632.61%Net margin, FY2022: -28136.99%Net margin, FY2023: -1622336.11%Net margin, FY2024: -101601.85%Net margin, FY2025: -1553513.10%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 -149.48%. Gross margin FY2022 -252.54%. Gross margin FY2023 -473.61%. Gross margin FY2024 97.18%. Gross margin FY2025 65.48%. Operating margin FY2021 -9579.65%. Operating margin FY2022 -27785.19%. Operating margin FY2023 -1604276.39%. Operating margin FY2024 -102464.08%. Operating margin FY2025 -1541666.67%. Net margin FY2021 -9632.61%. Net margin FY2022 -28136.99%. Net margin FY2023 -1622336.11%. Net margin FY2024 -101601.85%. Net margin FY2025 -1553513.10%.

Income trends

Revenue

84K JPY-92.59%

Operating income

−1.3B JPY-11.55%

Net income

−1.3B JPY-13.36%
Income trends across reported periods165.51M JPY−434.9M JPY−1.04B JPY−1.64B JPYRevenue, FY2021: 15.41M JPYRevenue, FY2022: 5.28M JPYRevenue, FY2023: 72K JPYRevenue, FY2024: 1.13M JPYRevenue, FY2025: 84K JPYOperating income, FY2021: −1.48B JPYOperating income, FY2022: −1.47B JPYOperating income, FY2023: −1.16B JPYOperating income, FY2024: −1.16B JPYOperating income, FY2025: −1.3B JPYNet income, FY2021: −1.48B JPYNet income, FY2022: −1.49B JPYNet income, FY2023: −1.17B JPYNet income, FY2024: −1.15B JPYNet income, FY2025: −1.3B JPYFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 15.41M JPY. Revenue FY2022 5.28M JPY. Revenue FY2023 72K JPY. Revenue FY2024 1.13M JPY. Revenue FY2025 84K JPY. Operating income FY2021 −1.48B JPY. Operating income FY2022 −1.47B JPY. Operating income FY2023 −1.16B JPY. Operating income FY2024 −1.16B JPY. Operating income FY2025 −1.3B JPY. Net income FY2021 −1.48B JPY. Net income FY2022 −1.49B JPY. Net income FY2023 −1.17B JPY. Net income FY2024 −1.15B JPY. Net income FY2025 −1.3B JPY.
Metric (JPY)FY2025FY2024FY2023FY2022FY2021
Revenue84K JPY1.13M JPY72K JPY5.28M JPY15.41M JPY
Cost of goods sold29K JPY32K JPY413K JPY18.61M JPY38.44M JPY
Gross profit55K JPY1.1M JPY−341K JPY−13.33M JPY−23.03M JPY
Research and development—888.06M JPY775.56M JPY1.17B JPY1.14B JPY
Selling, general, and administrative1.3B JPY273.96M JPY379.18M JPY285.25M JPY317.15M JPY
Operating expenses1.3B JPY1.16B JPY1.15B JPY1.45B JPY1.45B JPY
Interest income16K JPY69K JPY12K JPY20K JPY27K JPY
Interest expense———61K JPY362K JPY
Depreciation and amortization——395K JPY16.72M JPY35.12M JPY
Operating income−1.3B JPY−1.16B JPY−1.16B JPY−1.47B JPY−1.48B JPY
Net income−1.3B JPY−1.15B JPY−1.17B JPY−1.49B JPY−1.48B JPY

Company facts updated Aug 24, 2026.

4594.T peers

Chugai Pharmaceutical Co., Ltd. logo

4519.T

Chugai Pharmaceutical Co., Ltd.

¥6,989

-0.31%

Takeda Pharmaceutical Company Limited logo

4502.T

Takeda Pharmaceutical Company Limited

¥5,817

+0.92%

HOYA Corporation logo

7741.T

HOYA Corporation

¥25,030

+0.54%

Otsuka Holdings Co., Ltd. logo

4578.T

Otsuka Holdings Co., Ltd.

¥12,280

+0.70%

Daiichi Sankyo Company, Limited logo

4568.T

Daiichi Sankyo Company, Limited

¥2,866.5

+1.16%

Astellas Pharma Inc. logo

4503.T

Astellas Pharma Inc.

¥2,405

+0.75%

Continue in GoAI

Research 4594.T

research.disclaimer